BiotechTube
Home/Pipeline/SOT112

SOT112

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
SOTIO Biotech

About SOTIO Biotech

SOTIO Biotech is a private, clinical-stage biotech company headquartered in Prague, Czech Republic, with a strategic presence in the US and Europe. It is developing a diversified pipeline of immunotherapies, including the IL-15 superagonist nanrilkefusp alfa (SOT201) and several ADC candidates (SOT106, SOT109) targeting solid tumors. Backed by the PPF Group, the company leverages proprietary and partnered technology platforms to translate compelling science into patient benefit, with a business model centered on therapeutic development.

View full company profile

Therapeutic Areas

OncologySolid Tumors

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved